Study of asciminib for children with Ph+ CML
Part of Blood & lymphatic, Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 and 18 years old.
- You must have been diagnosed with Ph+ CML in the chronic phase.
- You must either be newly diagnosed (within 3 months before screening) or have had a poor response or intolerance to previous treatment.
- You must have a specific gene change (BCR::ABL1) that can be measured.
- You must have a good level of daily activity (performance status) for your age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial lets people who already have Philadelphia chromosome–positive (Ph+) leukemia and are benefiting from asciminib (or certain related medicines) continue treatment. It mainly tests whether ongoing care in a follow-on study is safe and workable for participants.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This study tests how well asciminib works and how safe it is for people with a type of blood cancer called chronic myeloid leukemia (CML). It helps see if asciminib is a good option compared to other standard treatments.
This early-phase study tests the right dose and safety of asciminib in children and teens with chronic myeloid leukemia (CML). It may help if your current or last CML medicine (a TKI) did not work well or caused side effects.
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
Hear when a new Chronic Myelogenous Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.